Roquefort Therapeutics PLC ROQ Presents Study Results at the ESGCT Conference
October 11 2022 - 2:00AM
RNS Non-Regulatory
TIDMROQ
Roquefort Therapeutics PLC
11 October 2022
11 October 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Roquefort Therapeutics Presents Study Results at the ESGCT
Conference
Abstract accepted at leading cell and gene therapy
conference
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class
medicines in the high value and high growth oncology market , is
pleased to announce that the results of its anti-cancer RNA
pre-clinical study will be presented later today at the 29(th)
European Society of Gene & Cell Therapy ("ESGCT") in Edinburgh.
The results demonstrate for the first time that a splice switching
RNA medicine can impair Midkine action by inducing a change in the
Midkine mRNA, that not only reduces full length Midkine but also
generates a non-functional shortened Midkine. Production of
truncated Midkine has been shown to reduce the size of cancers in
vivo and underpins the potential for anti-Midkine RNA medicines to
treat cancer in patients.
The co-authors are Drs Cale and Aung-Htut and Professor Wilton
from Murdoch University, and Dr Graham Robertson, Vice President of
Drug Discovery, Roquefort Therapeutics. The poster, number P482, is
embargoed until the presentation at the conference but will then be
available at the Roquefort Therapeutics website.
Further details of the event may be found on the ESGCT
website:
https://www.esgctcongress.com/poster-list
Ajan Reginald, Chief Executive Officer, commented:
"Congratulations to the team on reaching this milestone and
reporting the results at the ESGCT conference, Europe's leading
cell and gene therapy scientific meeting. RNA oligonucleotide-based
medicines are an innovative new approach to treat the cancers that
are resistant to existing drugs. At Roquefort Therapeutics, we are
developing a portfolio of anti-cancer medicines to block some of
the most novel cancer targets like Midkine and STAT-6. We have
shown blocking these factors kills cancer cells.
For the first time, an RNA medicine has been shown to switch-off
functional Midkine production in cancer cells. This
proof-of-concept study highlights the potential for a new class of
medicines blocking Midkine production to target some of the most
difficult to treat cancers. "
-Ends-
Enquiries:
Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan +44 (0)20 3918
Reginald (CEO) 8633
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of four best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- MK cell therapy with direct and NK-mediated anti-cancer action; and
-- siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMMBPTMTIBBLT
(END) Dow Jones Newswires
October 11, 2022 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024